Education
About Us
Working with TipRanks
Follow Us
Aprea Therapeutics Inc (APRE)
NASDAQ:APRE
APRE Stock Chart & Stats
$0.92
-$0.03(-0.72%)
At close: 4:00 PM EST
$0.92
-$0.03(-0.72%)
Day’s Range― - ―
52-Week Range$0.55 - $2.76
Previous CloseN/A
Volume2.88K
Average Volume (3M)55.77K
Market Cap
$10.55M
Enterprise Value-$7.42M
Total Cash (Recent Filing)$13.72M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.82
Next Earnings
Mar 26, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding11,451,118
10 Day Avg. Volume84,633
30 Day Avg. Volume55,770
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.94
Price to Sales (P/S)12.06
P/FCF Ratio-1.34
Enterprise Value/Market Cap-0.70
Enterprise Value/Revenue-15.20
Enterprise Value/Gross Profit1.18
Enterprise Value/Ebitda0.54
Forecast
1Y Price Target
$5.33Price Target Upside479.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.18
Revenue Forecast (FY)$300.00K
Bulls Say, Bears Say
Bulls Say
Competitive PositioningStructural and dosing differences versus a competitor, combined with early dose-related tumor responses, position the program to compete for leadership within the WEE1 inhibitor class.
Financing And Cash RunwayAn equity financing extends cash runway into 1Q27 and funds completion of dose escalation, reducing near-term funding risk for the lead program.
Safety And DosingFavorable safety and tolerability with continuous daily dosing and mostly mild adverse events enable further dose escalation and suggest a potentially wider therapeutic window than peers.
Bears Say
Clinical Data LimitationsClinical evidence is based on a small number of patients and several responses remain unconfirmed, creating significant risk that early signals may not validate in larger cohorts.
Program Pause And Operational RiskPausing a monotherapy study to conserve cash highlights funding constraints and could delay clinical readouts or the advancement of combination strategies.
Share DilutionAn equity raise dilutes existing shareholders and has applied downward pressure on the stock, which can offset positive momentum from clinical updates.
Aprea Therapeutics News
APRE FAQ
What was Aprea Therapeutics Inc’s price range in the past 12 months?
Aprea Therapeutics Inc lowest stock price was $0.55 and its highest was $2.76 in the past 12 months.
What is Aprea Therapeutics Inc’s market cap?
Aprea Therapeutics Inc’s market cap is $10.55M.
When is Aprea Therapeutics Inc’s upcoming earnings report date?
Aprea Therapeutics Inc’s upcoming earnings report date is Mar 26, 2026 which is in 19 days.
How were Aprea Therapeutics Inc’s earnings last quarter?
Aprea Therapeutics Inc released its earnings results on Nov 12, 2025. The company reported -$0.47 earnings per share for the quarter, missing the consensus estimate of -$0.34 by -$0.13.
Is Aprea Therapeutics Inc overvalued?
According to Wall Street analysts Aprea Therapeutics Inc’s price is currently Undervalued.
Does Aprea Therapeutics Inc pay dividends?
Aprea Therapeutics Inc does not currently pay dividends.
What is Aprea Therapeutics Inc’s EPS estimate?
Aprea Therapeutics Inc’s EPS estimate is -0.39.
How many shares outstanding does Aprea Therapeutics Inc have?
Aprea Therapeutics Inc has 11,451,118 shares outstanding.
What happened to Aprea Therapeutics Inc’s price movement after its last earnings report?
Aprea Therapeutics Inc reported an EPS of -$0.47 in its last earnings report, missing expectations of -$0.34. Following the earnings report the stock price went down -4.545%.
Which hedge fund is a major shareholder of Aprea Therapeutics Inc?
Currently, no hedge funds are holding shares in APRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aprea Therapeutics Inc
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
APRE Stock 12 Month Forecast
Average Price Target
$5.33
▲(479.35% Upside)
Technical Analysis
Ownership Overview
10.71% Insiders
2.72% Mutual Funds
9.97% Other Institutional Investors
76.32% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---